| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.038 | 0.6 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |